New hope for Hard-to-Treat blood cancers: mirdametinib trial opens

NCT ID NCT07061951

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 32 times

Summary

This study tests a drug called mirdametinib in 20 people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or not responded to prior treatments. The drug blocks a protein that helps cancer cells grow, aiming to shrink tumors or slow the disease. Participants will take the drug by mouth and be monitored for side effects and how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • City of Hope at Irvine Lennar

    RECRUITING

    Irvine, California, 92618, United States

    Contact

    Contact Phone: •••-•••-••••

  • UNC Lineberger Comprehensive Cancer Center

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.